Association between mortality and change (∆) from baseline to 12 months in disease-related variables by Cox regression analyses
| Variable | Median change (IQR) | Univariable analysis | Multivariable analysis | ||||
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| ∆ NT-proBNP (ng/L) | 375 (−258 to 1350) | 1.05* | 1.02 to 1.07 | 0.001 | 1.04* | 1.01 to 1.07 | 0.003 |
| ∆ eGFR (mL/min) | −5 (−12 to 1) | 1.00 | 0.98 to 1.01 | 0.732 | |||
| ∆ Albumin (g/L) | −1 (−3 to 1) | 1.01 | 0.95 to 1.06 | 0.840 | |||
| ∆ Troponin T (ng/L) | 12 (4 to 25) | 1.01 | 1.00 to 1.02 | 0.055 | |||
| ∆ IVSd (mm) | 0 (0 to 1) | 1.15 | 0.99 to 1.34 | 0.075 | 1.03 | 0.85 to 1.25 | 0.741 |
| ∆ LVPWd (mm) | 0 (0 to 1) | 1.12 | 0.98 to 1.27 | 0.099 | |||
| ∆ LVEF (%) | −1 (−6 to 4) | 1.00 | 0.98 to 1.02 | 0.886 | |||
| Increasing NYHA class | 0 (0 to 1) | 1.72 | 1.18 to 2.52 | 0.005 | 1.65 | 1.11 to 2.47 | 0.014 |
| ∆ Systolic blood pressure (mm Hg) | −1 (−11 to 9) | 1.00 | 0.99 to 1.01 | 0.741 | |||
| ∆ Diastolic blood pressure (mm Hg) | 1 (−7 to 7) | 1.00 | 0.98 to 1.01 | 0.556 | |||
| ∆ NAC ATTR stage | 0 (0 to 0) | 1.39 | 0.94 to 2.06 | 0.096 | |||
| ∆ 6MWT (m) | −11 (−70 to 16) | 0.85† | 0.70 to 1.02 | 0.080 | |||
Increasing NYHA class is displayed as a binary measure.
P-values meeting statistical significance (p<0.05) are highlighted in bold.
*HR for NT-proBNP is per 500 ng/L increase.
†HR for 6MWT distance is per 100 m increase; the remainder of HRs are per unit increase.
eGFR, estimated glomerular filtration rate; IVSd, interventricular septal thickness at end diastole; LVEF, left ventricular ejection fraction; LVPWd, left ventricular posterior wall thickness at end diastole; 6MWT, 6 min walk test; NAC ATTR stage, National Amyloidosis Centre transthyretin amyloidosis stage; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.